基于QSAR/QSSR的苯并三唑化合物选择性抑制PTP-1B的研究

蛋白酪氨酸磷酸酶1B (PTP-1B)特异性抑制剂是近年来治疗II型糖尿病药物研发的热点. PTP-1B与T细胞蛋白酪氨酸磷酸酶(TCPTP)同源性很高, 为了避免在使用PTP-1B抑制剂过程中对TCPTP产生交叉抑制, 则需要设计开发对PTP-1B具有高活性和高特异选择性的小分子化合物. 苯并三唑类化合物对PTP-1B的抑制活性很高, 并且其中一些化合物对PTP-1B表现出了较好的特异选择性, 具有良好的药用开发前景. 通过CoMFA和CoMSIA两种方法分别对该类化合物进行了三维定量结构-活性关系(3D-QSAR)和三维定量结构-选择性关系(3D-QSSR)研究, 并建立了相关的预测模型. 计算结果表明PTP-1B中的Arg24与化合物的氢键相互作用是提高选择性的重要因素, 并且在R2位引入氢键供体且体积较大的强供电子基团, 将有利于化合物抑制活性的提高, 而在R2位取代基的末端引入氢键受体且体积较大的强吸电子基团, 将有利于化合物选择性的提高.

Analyses Based on 3D-QSAR/QSSR of PTP-1B Selective Inhibitor-Benzotriazole Derivatives

Protein tyrosine phosphatase 1B(PTP-1B) has recently received much attention as a potential drug target in type 2 diabetes.T-cell protein tyrosine phosphatase(TCPTP) has an 80% homology to PTP-1B in the catalytic domains,and non-selective inhibition gives rise to severe side effects.Benzotriazole derivatives were found to be potent PTP-1B inhibitors,which provide a moderate degree of selectivity to PTP-1B over TCPTP.The 3D-QSAR and 3D-QSSR studies were conducted by comparative molecular field analysis(CoMFA...